Featured Posts
Blog
Fauci’s lasting legacy will be the damage he did to science and government
Anthony Fauci isn’t faring well in the court of public opinion. His recently divulged “diary” and subsequent July 29 appearance before the Senate Homeland…
News Release
FDA commissioner resignation opens opportunity for refocus on science over politics
After a somewhat tumultuous tenure, FDA commissioner Marty Makary is stepping down. While Dr. Makary made his mission to accelerate drug approval and bring…
Blog
Don’t hinder biosimilar development
In its most recent legislative session, the Florida legislature considered precluding pharmacy benefit managers (PBMs) from holding an investment interest in biosimilar manufacturing.
Search Posts
Op-Eds
The USDA’s Anti-Science Activism
Full Document Available in PDF U.S. Department of Agriculture Secretary Tom Vilsack must…
News Release
CEI Slams FDA Vote on Avastin
Washington, D.C., June 29, 2011 — An FDA advisory committee voted today to revoke the approval for breast cancer treatment from the drug Avastin.
Citation
Greg Conko on FDA Approval for Avastin
CEI Senior Fellow Greg Conko discusses the FDA's pending decision on whether or not to withdraw its approval of Avastin as a treatment for breast…
Comment
CEI Submits Comments on the Proposed Inspection System for Catfish
Full Document Available as a PDF The Competitive Enterprise Institute…
The Wall Street Journal
Why Your New Car Doesn’t Have a Spare Tire
Auto makers comply with fuel economy mandates by making cars lighter and more dangerous. Fewer tires, higher taxes. That may be what’s in store for…
The Wall Street Journal
There’s No ‘Average’ Cancer Patient
On June 28, the Food and Drug Administration (FDA) will hold a hearing to decide the fate of Avastin, a drug taken by thousands…